Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Market Access & Reimbursement

Set Alert for Market Access & Reimbursement

Latest From Market Access

Cost Sharing Fight: PhRMA Says Insurance Design Is Real Pricing Culprit

New report finds increase in use of deductibles and coinsurance charging members list prices.

Policy Pricing Debate

Multi-Company Product Listing Agreements On The Rise In Canada

The pan-Canadian Pharmaceutical Alliance has negotiated product listing agreements with three hepatitis C drug makers in one of its first major negotiations with multiple manufacturers. The pCPA may want to negotiate more deals with several companies at once, particularly those with drugs in crowded markets.

Market Access Pricing Strategies

Pfizer On Obamacare Rewind: No Short-Term Impact On Industry

Pfizer CEO Ian Read explains why industry has stayed on the sidelines during the current health reform debate and defends drug pricing practices during a speech to the National Press Club.

Policy Pricing Debate

India’s New National Health Care Policy Recycles Old Targets

India’s Health Minister says a new national health care roadmap marks a “huge milestone” towards fixing the country’s failing medical delivery system. But critics say while the scheme is a step in the right direction, it largely recycles old, unmet goals from years ago and caution that implementation will be key.

India Policy

Medicaid Block Grants: Allowing More State Flexibility To Limit Rx Coverage?

Medicaid block grant funding mechanism, which could allow states to bypass coverage requirements in the Medicaid drug rebate program, surfaces in House American Health Care Act.

Policy Medicaid

UK BioPharma Players Told 'Think Global, Act Local' For Post-Brexit World

The multi-faceted UK life sciences industry has been told to develop more connective tissue and encourage a more activist government industrial strategy to help it thrive after the country departs the European Union.

Brexit United Kingdom
See All